# COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications

> **NCT04771611** · PHASE2 · COMPLETED · sponsor: **James L. Kirkland, MD, PhD** · enrollment: 55 (actual)

## Conditions studied

- Covid19
- Coronavirus Infection

## Interventions

- **DRUG:** Fisetin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04771611
- **Lead sponsor:** James L. Kirkland, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-14
- **Primary completion:** 2022-09-27
- **Final completion:** 2022-09-27
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04771611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04771611, "COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04771611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*